144 related articles for article (PubMed ID: 8019514)
1. Silymarin and its components are inhibitors of beta-glucuronidase.
Kim DH; Jin YH; Park JB; Kobashi K
Biol Pharm Bull; 1994 Mar; 17(3):443-5. PubMed ID: 8019514
[TBL] [Abstract][Full Text] [Related]
2. Intestinal bacterial beta-glucuronidase activity of patients with colon cancer.
Kim DH; Jin YH
Arch Pharm Res; 2001 Dec; 24(6):564-7. PubMed ID: 11794536
[TBL] [Abstract][Full Text] [Related]
3. Hepatoprotective effect of lactic acid bacteria, inhibitors of beta-glucuronidase production against intestinal microflora.
Han SY; Huh CS; Ahn YT; Lim KS; Baek YJ; Kim DH
Arch Pharm Res; 2005 Mar; 28(3):325-9. PubMed ID: 15832821
[TBL] [Abstract][Full Text] [Related]
4. Characterization of beta-glucosidase and beta-glucuronidase of alkalotolerant intestinal bacteria.
Kim DH; Kang HJ; Park SH; Kobashi K
Biol Pharm Bull; 1994 Mar; 17(3):423-6. PubMed ID: 8019510
[TBL] [Abstract][Full Text] [Related]
5. Hepatoprotective activity of reduohanxiao-tang (yuldahanso-tang) is related to the inhibition of beta-glucuronidase.
Bae HS; Kim YS; Cho KH; Lee KS; Kim JJ; Lee HU; Kim DH
Am J Chin Med; 2003; 31(1):111-7. PubMed ID: 12723760
[TBL] [Abstract][Full Text] [Related]
6. Beta-glucuronidase inhibitory activity and hepatoprotective effect of 18 beta-glycyrrhetinic acid from the rhizomes of Glycyrrhiza uralensis.
Shim SB; Kim NJ; Kim DH
Planta Med; 2000 Feb; 66(1):40-3. PubMed ID: 10705732
[TBL] [Abstract][Full Text] [Related]
7. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1.
Miguez MP; Anundi I; Sainz-Pardo LA; Lindros KO
Chem Biol Interact; 1994 Apr; 91(1):51-63. PubMed ID: 8194125
[TBL] [Abstract][Full Text] [Related]
8. Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum.
Kim DH; Shim SB; Kim NJ; Jang IS
Biol Pharm Bull; 1999 Feb; 22(2):162-4. PubMed ID: 10077435
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant properties of silybin glycosides.
Kosina P; Kren V; Gebhardt R; Grambal F; Ulrichová J; Walterová D
Phytother Res; 2002 Mar; 16 Suppl 1():S33-9. PubMed ID: 11933137
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids.
Tang N; Wu D; Lu Y; Chen J; Zhang B; Wu W
Drug Metab Lett; 2009 Apr; 3(2):115-9. PubMed ID: 19601873
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of silybin nanosuspensions targeting liver.
Wang Y; Wang L; Liu Z; Zhang D; Zhang Q
J Biomed Nanotechnol; 2012 Oct; 8(5):760-9. PubMed ID: 22888746
[TBL] [Abstract][Full Text] [Related]
12. Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin.
Tung NT; Tran CS; Nguyen HA; Nguyen TD; Chi SC; Pham DV; Bui QD; Ho XH
Int J Pharm; 2019 Jan; 555():63-76. PubMed ID: 30448315
[TBL] [Abstract][Full Text] [Related]
13. Silybin is metabolized by cytochrome P450 2C8 in vitro.
Jancová P; Anzenbacherová E; Papousková B; Lemr K; Luzná P; Veinlichová A; Anzenbacher P; Simánek V
Drug Metab Dispos; 2007 Nov; 35(11):2035-9. PubMed ID: 17670841
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats.
Favari L; Pérez-Alvarez V
Arch Med Res; 1997; 28(1):11-7. PubMed ID: 9078581
[TBL] [Abstract][Full Text] [Related]
15. Oxidised derivatives of silybin and their antiradical and antioxidant activity.
Gazák R; Svobodová A; Psotová J; Sedmera P; Prikrylová V; Walterová D; Kren V
Bioorg Med Chem; 2004 Nov; 12(21):5677-87. PubMed ID: 15465345
[TBL] [Abstract][Full Text] [Related]
16. Identification of hepatoprotective flavonolignans from silymarin.
Polyak SJ; Morishima C; Lohmann V; Pal S; Lee DY; Liu Y; Graf TN; Oberlies NH
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5995-9. PubMed ID: 20231449
[TBL] [Abstract][Full Text] [Related]
17. A novel solid dispersion system for natural product-loaded medicine: silymarin-loaded solid dispersion with enhanced oral bioavailability and hepatoprotective activity.
Hwang du H; Kim YI; Cho KH; Poudel BK; Choi JY; Kim DW; Shin YJ; Bae ON; Yousaf AM; Yong CS; Kim JO; Choi HG
J Microencapsul; 2014; 31(7):619-26. PubMed ID: 24766208
[TBL] [Abstract][Full Text] [Related]
18. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant and hepatoprotective effects of silymarin phytosomes compared to milk thistle extract in CCl4 induced hepatotoxicity in rats.
El-Gazayerly ON; Makhlouf AI; Soelm AM; Mohmoud MA
J Microencapsul; 2014; 31(1):23-30. PubMed ID: 23808477
[TBL] [Abstract][Full Text] [Related]
20. [Studies of the metabolism and excretion of silybin in the rat].
Bülles H; Bülles J; Krumbiegel G; Mennicke WH; Nitz D
Arzneimittelforschung; 1975 Jun; 25(6):902-5. PubMed ID: 1174327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
